Skip to content
N

Niaré Adama

Publications (7)

Study by Molecular Docking of the Interactions between Dihydroorotate Dehydrogenase and a Series of Inhibitors of Pyrrole Derivatives for the treatment of Malaria

Niaré Adama, Attia Yapo John Alex, Djako Akassa Marius Bernard, Kambiré Sobamfou Marius, Dembélé Georges Stéphane, Kouadio Assandé Moise, Koné Mamadou Guy-Richard, Yves Kily Hervé Fagnidi & Soro Doh · Asian Journal of Chemical Sciences · 2025

Malaria, although a curable disease, continues to be the most important infectious disease in terms of incidence and mortality worldwide. It is a potentially fatal disease caused by parasites transmitted to people through the bites of infected female Anopheles mosquitoes. This di...

Open access Research Article 10.9734/ajocs/2025/v15i1352

Computer-Assisted Design of Hydroxamic Acid Derivatives Inhibitors of M1 Metallo Aminopeptidase of Plasmodium falciparum with Favorable Pharmacokinetic Profile

Niaré Adama, Hermann N’Guessan, Brice Dali & Eugene Megnassan · Journal of Pharmaceutical Research International · 2022

We virtually design here new subnanomolar range antimalarial, inhibitors of plasmodium falciparum M1 Aminopeptidase (PfA-M1), by means of structure-based molecular design. We developed the complexation QSAR models from Hydroxamic Acid derivatives (AHO). A linear correlation was e...

Open access Research Article 10.9734/jpri/2022/v34i607271

Identification of Novel Polyketide Synthase 13 of Mycobacterium Tuberculosis Inhibitors: A Modelling Approach Using the Pharmacophore Method -Based Virtual Screening

Djako Akassa Marius Bernard, Niaré Adama, Fofana Issouf, Moussé Logbo Mathias, Kéita Mélalie & Megnassan Eugène · Journal of Advances in Medical and Pharmaceutical Sciences · 2025

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. It remains a major public health problem worldwide. In 2022, 10.6 million people contracted tuberculosis and 1.3 million died from it.  This manuscript presents our work, the aim of which is to find new i...

Open access Research Article 10.9734/jamps/2025/v27i6784

Modeling of the Thermal Behaviour of Acid Phosphatase from Breadfruit (Artocarpus communis) Seeds: Equilibrium Model Approach

Kambiré Sobamfou Marius, Gnanwa Mankambou Jacques, Niaré Adama, Karamoko Bonito Aristide & Dembélé Georges Stéphane · Biotechnology Journal International · 2025

Stabilization of enzymes is crucial to improve their durability and efficiency in various industrial applications. Thus, the search for new thermostable enzymes is a booming field. The seeds of Artocarpus communis are rich in acid phosphatases. Study of these enzymes could also b...

Open access Research Article 10.9734/bji/2025/v29i2770

In silico Design of Sulfenylated 5-Aminopyrazole Derivatives, Novel Butyrylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease

Issouf Soro, Manchondenin Soro, Ludovic Akonan, Niaré Adama, Boris Davy Bekono, Raymond Kre N’guessan & Eugene Megnassan · Asian Journal of Chemical Sciences · 2026

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with cholinergic dysfunction, and butyrylcholinesterase (BuChE) becomes increasingly relevant as disease pathology progresses. This study aimed to design sulfenylated 5-aminopyrazole (APS) analogues as potential...

Open access Research Article 10.9734/ajocs/2026/v16i5478

Molecular Modeling and Virtual Screening: Application to Computer-Aided Design of Anticancer Inhibitors of Human Dihydroorotate Dehydrogenase

N’doman Gossan Roméo, Bibila Mayaya Bisseyou Yvon, Djako Akassa Marius Bernard, Niaré Adama, Akori Esmel Elvice, Kéita Mélalie & Megnassan Eugène · Journal of Pharmaceutical Research International · 2025

Abnormal and uncontrolled cell growth leading to dysfunction of cellular metabolism causes a serious disease called cancer. In 2022, 20 million people had cancer and 9.7 million died. Cancer is a real health problem given the number of deaths caused by this disease. This article...

Open access Research Article 10.9734/jpri/2025/v37i87734

Computer-Aided Design of Imidazo [4.5-c] Pyridin-4-one Derivatives as Antagonists of the Angiotensin II Type 1 (AT1) Receptor

Abel Landry Tebily, Akoun Abou, Issouf Soro, Abdoulaye Djandé, Niaré Adama & Megnassan Eugène · Journal of Pharmaceutical Research International · 2026

Over the past decade, drug resistance has emerged as a major challenge in the treatment of high blood pressure. This report evaluates new imidazo[4.5-c]pyridin-4-one compounds designed to inhibit the AT1 enzyme, and highlights their therapeutic potential, supported by favourable...

Open access Research Article 10.9734/jpri/2026/v38i57837